Xolair (omalizumab) - Roche, Novartis
Nucala (mepolizumab) - GSK
Fasenra (benralizumab) - AstraZeneca
Dupixent (dupilumab) - Sanofi, Regeneron
https://jcf-25-s2.elsevierdigitaledition.com/
 
J. Barry 1; I. Gutman 2; K. Patel 3; M. Trieu 1; J. Bailey 1; D. Conrad 4; P. Akuthota 1
 
Sep 9, 2026
 
Prev Next